Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of BMI2004 (Recombinant Hyaluronidase) in Healthy Adults
NCT05922813Phase 1Completed
- Sponsor
- BMI OrganBank
- Start
- Jun 2022
- Primary completion
- Mar 2023
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 1, randomised trial of BMI-2004 (2 arms), sponsored by BMI OrganBank. Primary endpoints: Incidence of drug allergic reaction at 48 hours and Incidence of adverse events at 48 hours. Started Jun 2022; status: completed.
02
Drugs
BMI-2004
Beyond the preview
Go deeper on NCT05922813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05922813.